Skip to main content
Caplight Logo









Sentante

Sentante

Private
KaunasHealthcare & Life Scienceshttps://sentante.com/

Last Round

Grant

Jul 9, 2024

Total Funding Raised

$9.63M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sentante is a medical technology company that develops a fully robotic teleoperated system for endovascular interventions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Industrial Robotics, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Application

Keywords

medical roboticsteleoperated surgeryendovascular roboticsrobotic surgerytelesurgeryhaptic feedbackremote surgerythrombectomymedical deviceneurointerventionvascular surgerysurgical roboticsrobotic-assisted surgerytelemedicinesurgical tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sentante Comparables

Compare Sentante with similar companies based on industry and business-model similarity.

Sentante comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanoflex Robotics
92%
Remedy Robotics
90%
XCath
89%

Sentante Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 9, 2024
SeedDec 21, 2023
GrantJun 16, 2021

Key People

Founding team and executive leadership

Evaldas Kalvaitis

Cofounder & COO

Founding Team

Edvardas Satkauskas

Chief Executive Officer

Executive Team

Sentante Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 122% MoM, reaching 1.2K.

  • Aug 2, 2026

    Grew 18% QoQ, from 33 to 39 employees.

Recent news

Latest coverage and updates

  • integrates_withAug 25, 2026

    Sentante integrates with NVIDIA Corporation.

  • launchesJul 15, 2026

    Sentante launched precision-controlled digital indeflator - dubbed 'Inflante' on Jul 15th '26.

  • receives_awardJun 29, 2026

    Sentante received award Groundbreaking Technology at Surgical Robotics Technology (SRT) Industry Awards 2026 on Jun 29th '26.

Sentante Filings

Explore SEC and related filing metadata, where available.

Sentante filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sentante's valuation, stock price, and market status.

Is Sentante a public or private company?

Sentante is a private company.

What is the current stock price of Sentante?

Sentante is a private company with no public stock price. No recent secondary market data is available.

How much is Sentante worth (valuation)?

Valuation information for Sentante is not publicly available.

Can I buy Sentante stock?

Sentante shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sentante's last funding round?

Sentante's most recent funding round was Grant on July 9, 2024.

Who are the main investors in Sentante?

Key investors in Sentante include Practica Capital.

Will Sentante IPO soon?

No public IPO plans have been announced for Sentante.

How can I track Sentante secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sentante's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersKaunas
Employee Range39
Year Founded2017
Last FundingJul 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?